

Teva's Economic Impact in 2020



As the leading provider of generic medicines, we increase access to quality, affordable treatments for the nearly 200 million patients we serve each day, while supporting the sustainability of healthcare systems.

In a year of unique challenges, we continued to contribute to our communities through jobs, economic output and savings from our generic medicines.

Here's a look at our global economic impact in 15 countries where we operate, based on an independent analysis by Matrix Global Advisors.



Nearly **40,000** full-time-equivalent employees across **60** countries



85B tablets and capsules and **785M** sterile units sold



60 manufacturing and **25** clinical development sites



\$1B invested in R&D

Supporting the economy

Teva's economic activity in 15 countries*:

supported nearly **250,000** jobs

contributed **\$52.0B** to economic output

generated **\$11.7B** in labor income

Increasing access to quality medicines




Nearly **\$43.1B** in savings from generic medicines across **14** countries



800 new generic medicine approvals

Savings from our generic medicines



Combining our strength in generic medicines and knowledge of specialty drugs to advance biosimilars



10 biosimilars approved or in development, in-house or with partners

\$288M estimated annualized savings from TRUXIMA® in the United States

Biosimilars are less-costly versions of branded biologic drugs—complex medicines made from living cells or organisms that treat life-threatening and chronic diseases

A closer look at Teva's economic activity



In the United States:

supported **57,000+** jobs

contributed **\$15.7B** to economic output

generated **\$4.4B** in labor income

\$28.8B in savings from generic medicines **\$374.6B** over the last decade



Across 9 European countries:

supported **100,000+** jobs

contributed **\$29.5B** to economic output

generated **\$5.6B** in labor income

\$9.6B in savings from generic medicines

Making an impact beyond our business



Donated **\$571M+** worth of medicines to patients in need

COVID-19 response



No pandemic-related job losses



Maintained consistent supply of medicines



Donated **\$30M** worth of medicines and PPE, medical equipment and disinfectant



Selected at the Ministry of Health public tender to exclusively distribute the Pfizer vaccine in Israel

Read more about our impact in [Teva's Economic Impact Report](#)

*Bulgaria, Canada, Chile, France, Germany, India, Israel, the Netherlands, Poland, Spain, Switzerland, Sweden, Ukraine, United Kingdom, United States

Data in the report is based on independent analyses conducted by Matrix Global Advisors (MGA), an economic policy consulting firm in Washington, DC, for 15 of the 60 countries in which Teva operates. MGA used IMPLAN models, widely utilized across government, academia, non-profit and corporate settings, to examine how Teva's and Teva employees' spending ripples through economies around the world.